-       Clinical Trials 
- April 2025
-  120 Pages 
- Global 
   From       €1424EUR$1,600USD£1,253GBP 
      €1780EUR$2,000USD£1,567GBP 
          -       Report 
- February 2025
-  200 Pages 
- Global 
   From       €3995EUR$4,490USD£3,517GBP 
            -       Clinical Trials 
- April 2025
-  50 Pages 
- Global 
   From       €1068EUR$1,200USD£940GBP 
      €1335EUR$1,500USD£1,175GBP 
            -       Clinical Trials 
- April 2025
-  60 Pages 
- Global 
   From       €1068EUR$1,200USD£940GBP 
      €1335EUR$1,500USD£1,175GBP 
            -       Report 
- March 2025
-  150 Pages 
- Global 
   From       €3426EUR$3,850USD£3,016GBP 
      €4316EUR$4,850USD£3,799GBP 
           -       Clinical Trials 
- January 2025
-  108 Pages 
- Global 
   From       €3070EUR$3,450USD£2,702GBP 
          -       Report 
- September 2023
-  180 Pages 
- Global 
   From       €4138EUR$4,650USD£3,642GBP 
            -       Report 
- June 2024
-  200 Pages 
- Global 
   From       €5660EUR$6,360USD£4,982GBP 
      €7074EUR$7,950USD£6,227GBP 
            -       Report 
- June 2024
-  200 Pages 
- Global 
   From       €5660EUR$6,360USD£4,982GBP 
      €7074EUR$7,950USD£6,227GBP 
            -       Report 
- January 2022
-  60 Pages 
- Global 
   From       €2812EUR$3,160USD£2,475GBP 
      €3515EUR$3,950USD£3,094GBP 
            -       Report 
- May 2024
-  131 Pages 
- Global 
   From       €4916EUR$5,524USD£4,327GBP 
      €5783EUR$6,499USD£5,091GBP 
            -       Report 
- May 2024
-  129 Pages 
- Global 
   From       €4916EUR$5,524USD£4,327GBP 
      €5783EUR$6,499USD£5,091GBP 
            -       Report 
- May 2024
-  140 Pages 
- Global 
   From       €4916EUR$5,524USD£4,327GBP 
      €5783EUR$6,499USD£5,091GBP 
          -       Report 
- April 2022
-  64 Pages 
- Global 
   From       €3115EUR$3,500USD£2,742GBP 
          -       Drug Pipelines 
- November 2020
-  114 Pages 
- Global 
   From       €1780EUR$2,000USD£1,567GBP 
          -       Report 
- January 2023
-  92 Pages 
- Global 
   From       €4449EUR$5,000USD£3,917GBP 
          -       Report 
- August 2024
-  95 Pages 
- Global 
   From       €3500EUR$4,213USD£3,189GBP 
       
      Ataxia is a neurological disorder that affects the coordination of movement. Ataxia drugs are used to treat the symptoms of this disorder, which can include difficulty walking, speaking, and swallowing. These drugs are part of the larger Central Nervous System (CNS) drug market, which includes drugs used to treat a variety of neurological and psychiatric disorders. Ataxia drugs are typically prescribed to improve coordination and balance, as well as to reduce the risk of falls.
Ataxia drugs are    typically divided into two categories: symptomatic and disease-modifying. Symptomatic drugs are used to reduce the symptoms of ataxia, while disease-modifying drugs are used to slow the progression of the disorder. Common symptomatic drugs include benzodiazepines, anticholinergics, and anticonvulsants. Disease-modifying drugs include immunomodulators, gene therapy, and stem cell therapy.
Some companies in the Ataxia Drug market include AbbVie, Biogen, Merck, Novartis, and Pfizer. Show Less   Read more